Indication (pathologie):
Chronic renal failure
Identifiant SNOMED-CT:
SCTID 90688005
Etudes cliniques
-
L'éducation thérapeutique du patient insuffisant rénal chronique, quels bénéfices?Recrutement: Ouvert
-
A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic AcidosisIndication (pathologie):Chronic kidney diseaseIdentifiant SNOMED-CT:SCTID 709044004Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A 12 month, partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal antibody, CFZ533, in de novo and maintenance kidney transplant recipientsIndication (pathologie):Transplant of kidneyIdentifiant SNOMED-CT:SCTID 70536003Phase de l'étude: Phase IIRecrutement: Ouvert
-
Prevalence of asymptomatic bacteriuria among kidney transplant recipients: a multicenter, prospective, cross-sectional studyIndication (pathologie):Transplant of kidneyIdentifiant SNOMED-CT:SCTID 70536003Recrutement: Ouvert
-
A randomized, multicenter, double-blind, parallel-group, active-control study of the efficacy and safety of sparsentan for the treatment of immunoglobulin A nephropathyIndication (pathologie):Immunoglobulin A nephropathyIdentifiant SNOMED-CT:SCTID 236407003Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A phase III, randomized, double-blind, active comparator-controlled study to evaluate the efficacy and safety of MK-8228 (Letermovir) versus valganciclovir for the prevention of human cytomegalovirus (CMV) disease in adult kidney transplant recipientsIndication (pathologie):Human cytomegalovirusIdentifiant SNOMED-CT:SCTID 243579005Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A randomized, double-blind, placebo controlled study to evaluate efficacy and safety of Nefecon in patients with primary IGA nephropathy at risk of progressing to send-stage renal diseaseIndication (pathologie):Primary immunoglobulin A nephropathyIdentifiant SNOMED-CT:SCTID 68779003Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A randomized, double-blind, placebo-controlled, phase 2 study to evaluate the safety and efficacy of avacopan (CCX168) in patients with c3 glomerulopathyIndication (pathologie):Glomerular diseaseIdentifiant SNOMED-CT:SCTID 197679002Phase de l'étude: Phase IIRecrutement: Ouvert
-
Aldosterone antagonist chronic hemodialysis interventional survival trial (ALCHEMIST)Indication (pathologie):Maladie rénale terminale en hémodialyseIdentifiant SNOMED-CT:46177005Indication (pathologie):Maladie cardiovasculaireIdentifiant SNOMED-CT:49601007Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A phase IV prospective study, non-randomized, multi-center, multi-national, open-label cohort to assess thrombotic microangiopathy (TMA) disease manifestation in patients with atypical hemolytic uremic syndrome (aHUS) participating in the M11-001 aHUS RegistryIndication (pathologie):Syndrome d’hémolyse-urémie atypique (SHUa)Identifiant SNOMED-CT:78209002Phase de l'étude: Phase IVRecrutement: Ouvert
-
Single arm study of ALXN1210 in complement inhibitor treatment-naïve adult and adolescent patients with atypical hemolytic uremic syndrome (aHUS)Indication (pathologie):Syndrome d’hémolyse-urémie atypique (SHUa)Identifiant SNOMED-CT:78209002Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A phase II, uncontrolled, two-stage, dose-escalation cohort study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and clinical activity of OMS721 in adults with thrombotic microangiopathiesIndication (pathologie):Microangiopathie thrombotique (MAT)Identifiant SNOMED-CT:126729006Phase de l'étude: Phase IIRecrutement: Ouvert
-
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and clinical diagnosis of diabetic kidney disease in addition to standard of careIndication (pathologie):Néphropathie diabétiqueIdentifiant SNOMED-CT:SCTID 771000119108Indication (pathologie):Maladie cardiovasculaireIdentifiant SNOMED-CT:49601007Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney diseaseIndication (pathologie):Néphropathie diabétiqueIdentifiant SNOMED-CT:771000119108Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A Randomized, double-blind, active-controlled study to evaluate the safety and efficacity of CCX168 (avacopan) in patients with anti-neutrophil cytoplasmic antibody (anca-associated vaculitis treated concomitantly with rituximab or cyclophosphamide / azathioprine.Indication (pathologie):Vasculite à anticorps anti-cytoplasme des polynucléaires neutrophiles (ANCA) (y compris glomérulonéphrite)Identifiant SNOMED-CT:722191003Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A 6-year, multicentre, non-interventional, post-authorisation safety study for patients prescribed JINARC® for autosomal dominant polycystic kidney diseaseIndication (pathologie):Polykystose rénale autosomique dominante (ADPKD)Identifiant SNOMED-CT:737295003Recrutement: Ouvert
-
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal transplant efficacy and safety outcomes with an everolimus-based regimen (TRANSFORM)Indication (pathologie):Transplantation rénaleIdentifiant SNOMED-CT:737295003Phase de l'étude: Phase IIIRecrutement: Ouvert